New study reveals "enormous medical value" of Lundbeck's new migraine drug compared to generics, Head of R&D says
Lundbeck's migraine treatment Vyepti is more expensive than traditional treatment options, which are available as generic drugs, but EVP and Head of R&D Johan Luthman says recently publicized phase III data supports the pricing assessment for the drug.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Lundbeck's newest study of migraine therapy vyepti will not result in new indications for the drug or expand the enclosed patient information leaflet in any major way. Nonetheless, Head of Research and Development at Lundbeck Johan Luthman is pleased about the results.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck presents positive results from migraine drug trial
For subscribers
Lundbeck CEO considers stepping up marketing of Vyepti
For subscribers
